Related Experiment Video
Updated: Jun 13, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
[Diabetes and heart failure]
Christian A Schneider1, Roman Pfister, Erland Erdmann
1Klinik III für Innere Medizin, Herzzentrum, Universität zu Köln, Köln, Germany. Christian.Schneider@uk-koeln.de
Insights
Type 2 diabetes commonly leads to heart failure, which has a poor prognosis. Current treatment guidelines for heart failure apply, but optimal blood glucose control and HbA1c targets for diabetic patients remain unknown due to a lack of specific trials.
Area of Science:
- Cardiology
- Endocrinology
- Diabetology
Context:
- Heart failure is a frequent and serious complication in patients with type 2 diabetes.
- Established heart failure diagnostic and treatment standards are applicable, yet specific trials for this population are absent.
Purpose:
- To review the current understanding and management of heart failure in type 2 diabetes patients.
- To highlight the lack of diabetes-specific evidence for optimal glycemic control targets and treatments.
Summary:
- Patients with type 2 diabetes and heart failure should adhere to general heart failure management principles.
- Optimal HbA1c targets and glucose-lowering strategies require further investigation through prospective, randomized trials.
- Treatment decisions should prioritize low side effect profiles, combination therapy, patient convenience, and cost-effectiveness.
Impact:
- Informs clinical practice by emphasizing the need for evidence-based, individualized treatment approaches.
- Identifies critical knowledge gaps in managing comorbid type 2 diabetes and heart failure.
- Guides future research priorities for improving outcomes in this high-risk patient group.
Abstract:
Heart failure is a common complication of type 2 diabetes and bears a poor prognosis. For patients with diabetes and heart failure the commonly accepted standards for diagnosis and treatment of heart failure are to be applied, although prospective diabetes- specific trials are lacking. The optimum HbA(1c) target value as well as the optimum blood glucoselowering treatment are not known. Due to an absence of prospective randomized trials the treatment should follow general therapeutic principles (low incidence of side effects, combination therapy, patient-friendly dosage, costs).
Related Concept Videos
Heart Failure I: Introduction
Heart Failure V: Medical Management
Heart Failure Drugs: Diuretics
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure III: Clinical Manifestations
Heart Failure II: Pathophysiology
